Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:04 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)
NCT00923247 · National Cancer Institute (NCI) · PHASE1/PHASE2 · terminated · last registry update 2018-11-29 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Terminated due to slow accrual,primary endpoint reached \& investigator left NIH.” | – | Registry record, National Cancer Institute (NCI) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SRC within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-08-20Also stopped (terminated): National Cancer Institute (NCI), saracatinib (NCT00397878)
- 2019-08-14Results posted on the registry: Yale University, AZD0530 100mg daily + AZD0530 125mg daily (NCT02167256)
- 2019-07-31Results posted on the registry: Joyce Marie Slingerland, MD, Anastrozole + AZD0530 (saracatinib) (NCT01216176)
- 2019-07-23Results posted on the registry: National Cancer Institute (NCI), Vandetanib (NCT02015065)
- 2019-03-26Also stopped (terminated): Barbara Ann Karmanos Cancer Institute, carboplatin + paclitaxel (NCT00459121)
- 2018-11-14Results posted on the registry: Pfizer, Bosutinib + Imatinib (NCT02130557)
- 2018-11-14Also stopped (terminated): M.D. Anderson Cancer Center, ZD6474 (ZACTIMA) (NCT00745732)
- 2018-02-05Also stopped (terminated): Cancer Research UK, AZD0424 (NCT01668550)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision